News Column

Data on Hepatocellular Cancer Reported by Researchers at Institute of Nuclear Energy Research (Sorafenib increases efficacy of vorinostat against...

July 8, 2014



Data on Hepatocellular Cancer Reported by Researchers at Institute of Nuclear Energy Research (Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-kappa ...)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology. According to news reporting out of Taoyuan, Taiwan, by NewsRx editors, research stated, "Sorafenib is effective for patients with advanced hepatocellular carcinoma (HCC) and particularly for those who are unsuitable to receive life-prolonging transarterial chemoembolization. The survival benefit of sorafenib, however, is unsatisfactory."

Our news journalists obtained a quote from the research from the Institute of Nuclear Energy Research, "Vorinostat also known as suberoylanilide hydroxamic acid (SAHA) is a histone deacetylase (HDAC) inhibitor with anti-HCC efficacy in preclinical studies. SAHA induces nuclear factor x-light-chain-enhancer of activated B cells (NF-kappa B) activity in vitro, which may lead to cancer cell progression and jeopardize cytotoxic effect of SAHA in HCC. The goal of this study was to investigate whether sorafenib enhances SAHA cytotoxicity against HCC through inhibition of SAHA-induced NF-kappa B activity. The human HCC cell line Huh7 transfected with dual reporter genes, luciferase (luc) and thymidine kinase (tk) with NF-kappa B response elements, was co-transfected with red fluorescent protein (rfp) gene for non-invasive molecular imaging to assess NF-kappa B activity and living cells simultaneously. Cell viability assay, DNA fragmentation, western blotting, electrophoretic mobility shift assay (EMSA) and multiple modalities of molecular imaging were used to assess the combination efficacy and mechanism of sorafenib and SAHA. The administration of high-dose SAHA (10 mu M) with long treatment time (48 h) in vitro, and 25 mg/kg/day by gavage in HCC-bearing nude mice to induce NF-kappa B activity were performed. Sorafenib inhibited SARA-induced NF-kappa B activity and the expression of NF-kappa B-regulated effector proteins while it increased the efficacy of SAHA against HCC both in vitro and in vivo. The mechanism of sorafenib to enhance SAHA efficacy on HCC is through the suppression of ERK/NF-kappa B pathway, which induces extrinsic and intrinsic apoptosis."

According to the news editors, the research concluded: "Combination of sorafenib and SAHA may have the potential as new strategy against HCC."

For more information on this research see: Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-kappa B signaling. International Journal of Oncology, 2014;45(1):177-188. International Journal of Oncology can be contacted at: Spandidos Publ Ltd, Pob 18179, Athens, 116 10, Greece (see also Oncology).

Our news journalists report that additional information may be obtained by contacting F.T. Hsu, Inst Nucl Energy Res, Div Radioisotope, Taoyuan 32546, Taiwan. Additional authors for this research include Y.C. Liu, I.T. Chiang, R.S. Liu, H.E. Wang, W.J. Lin and J.J. Hwang.

Keywords for this news article include: Asia, Taiwan, Taoyuan, Genetics, Oncology, NF-kappa B, Nanotechnology, Nuclear Proteins, Molecular Imaging, DNA-Binding Proteins, Emerging Technologies, Transcription Factors, Hepatocellular Carcinoma

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters